Doug Drysdale serves as the CEO of Cybin, drawing on a rich history of executive leadership in the pharmaceutical industry. As a seasoned professional, he has successfully built and revived three pharmaceutical companies. Notably, under his stewardship, Alvogen, a global pharmaceutical company, burgeoned from inception to amass $450 million in revenues across 35 countries. Drysdale's hands-on approach extended to chairing the board of directors of a NASDAQ-listed company, reaffirming his capabilities in corporate governance.

His strategic acumen is further demonstrated in his role in the recapitalization of NASDAQ-listed Pernix Therapeutics, where he spearheaded a fundraising drive that raised $65 million. Over the course of his career, Drysdale has marshaled approximately $4 billion in both public and private capital. This fund-raising prowess speaks to Drysdale's credibility in financial markets and his ability to inspire investor trust in his ventures.

In recognition of his entrepreneurial achievements, Drysdale was honored with the E&Y Entrepreneur of the Year award in 2012. He holds a bachelor’s degree in Microbial and Molecular Biology from the University of East Anglia in the United Kingdom.

Pharmaceutical, Business Leadership, Leadership Entrepreneurship, Venture Capital, Finance, Investing, Mental Health, Milken Institute, Biotechnology, Healthcare, Depression,